Ann: Cognitive improvement demonstrated with Xanamem, page-387

Hi Micheal,

I have to sincerely apologise, there is actually a really good article above the blog posts (which your post automatically scrolls to at the bottom with comments). I should have looked a bit closer with trying to have a conversation with kids on a sleep over. .

Inflammatory processes in the brain are now quite a big research area in AD (which is where cortisol theory fits in); as are Tau proteins. Beta Amyloid plaque theory has been a big failure in AD clinical trials time & time again. In fact, autopsies have shown Amyloid plaque build up in brains of people who have no signs of dementia during their life time.

The exciting thing for ACW is that albeit a trial failure of 10mg daily for Xanamem in a phase 2 in AD, we are seeing cognitive improvement in healthy older adults in a Ph1 dose escalation study @20mg (Xanahes). Healthy trial participants are a given in a Ph1, except in certain circumstances ie cancer & this will be all down to Ethics approval. The ability of this drug to cross the BBB (blood brain barrier) to lower cerebral cortisol levels was actually amazing in its own right. This is one of the most difficult things to achieve safely in neurological diseases & to then to show efficacy....Big Pharmas are aware of ACW & Xanamem. Happy Days